Ascendis制药 ASND 深 沪
等待开盘 01-31 09:30:00 美东时间
224.31
+0.360
+0.16%
华盛通- 最 高228.505
- 今 开224.00
- 成交量 7.61万股
- 最 低 221.52
- 昨 收 223.95
- 总市值 138.39亿
- 52周最高 242.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 118.03
- 委 比 0.00%
- 总股本 6169.52万
- 历史最高 242.00
- 量 比 0.28
- 振 幅 3.12%
- 历史最低 11.92
- 每 手 1
- 风险率 25.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Barclays Initiates Coverage On Ascendis Pharma with Overweight Rating, Announces Price Target of $342
Barclays analyst Eliana Merle initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Overweight rating and announces Price Target of $342.
01-28 22:33
Ascendis Pharma rises amid takeover speculation
Ascendis Pharma (ASND) gained 7.5% amid some takeover speculation. There's talk that a Switzerland-based pharma company and another European firm are eyeing Ascendis (ASND), according to traders, who ...
01-23 00:47
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $330
Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $322 to $330.
01-20 23:48
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
<p><p>Ascendis Pharma announced Phase 2 COACH trial results showing that once-weekly TransCon CNP and TransCon hGH combination therapy in children with achondroplasia demonstrated durable growth, improved body proportionality, and exceeded 97th-percentile annualized growth velocity without compromising safety or tolerability at 52 weeks. The combination therapy also improved arm span beyond the 84th percentile and maintained bone age. All childre...
01-08 21:01
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
TD Cowen Reiterates Buy on Ascendis Pharma, Maintains $325 Price Target
TD Cowen analyst Yaron Weber reiterates Ascendis Pharma (NASDAQ:ASND) with a Buy and maintains $325 price target.
01-07 23:48
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Ascendis Pharma A/S announced its executives will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, to provide a business update. The presentation will be live streamed on their investor relations website, with a replay available for 30 days. Ascendis is a global biopharmaceutical company utilizing its TransCon technology to develop innovative therapies for unmet medical needs.
01-05 13:30
